Dyslipidemias

Metabolic Diseases
16
Pipeline Programs
9
Companies
14
Clinical Trials
2 recruiting
4
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
6
0
2
5
Early DiscoveryClinical DevelopmentMarket

On Market (4)

Approved therapies currently available

U
ANTARA (MICRONIZED)Approved
fenofibrate
Unknown Company
Peroxisome Proliferator Receptor alpha Agonist [EPC]oral2004
U
FENOFIBRATEApproved
fenofibrate
Unknown Company
Peroxisome Proliferator Receptor alpha Agonist [EPC]oral2020
U
FENOFIBRATE (MICRONIZED)Approved
fenofibrate
Unknown Company
oral2003
U
TRIGLIDEApproved
fenofibrate
Unknown Company
oral2005

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Abbott
AbbottABBOTT PARK, IL
1 program
1
fenofibratePhase 41 trial
Active Trials
NCT01462877Completed506Est. Mar 2014
NewAmsterdam Pharma
NewAmsterdam PharmaNARRDEN, Netherlands
6 programs
4
2
Combination TherapyPhase 31 trial
ObicetrapibPhase 31 trial
ObicetrapibPhase 21 trial
ObicetrapibPhase 21 trial
Obicetrapib 5mgPhase 21 trial
+1 more programs
Active Trials
NCT05266586CompletedEst. Sep 2022
NCT04753606CompletedEst. Aug 2021
NCT04770389CompletedEst. Jun 2021
+3 more trials
Arrowhead Pharmaceuticals
2 programs
1
1
ARO-APOC3Phase 21 trial
ARO-ANG3Phase 11 trial
Active Trials
NCT03747224Completed93Est. May 2021
NCT05413135Completed418Est. Sep 2025
Jazz Pharmaceuticals
Jazz PharmaceuticalsCA - Palo Alto
1 program
1
GWP42003Phase 21 trial
Active Trials
NCT01217112Completed62Est. Sep 2012
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
2 programs
2
LY3202328Phase 11 trial
LY3885125Phase 11 trial
Active Trials
NCT02714569Completed60Est. Feb 2017
NCT06007651Terminated49Est. Feb 2025
Sanofi
SanofiPARIS, France
1 program
Guideline recommended feedbackN/A1 trial
Active Trials
NCT03994575Completed248Est. May 2021
Novartis
NovartisBASEL, Switzerland
1 program
Lipid panelN/A1 trial
Active Trials
NCT06388668Recruiting100Est. May 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Abbottfenofibrate
NewAmsterdam PharmaCombination Therapy
NewAmsterdam PharmaObicetrapib
NewAmsterdam Pharmaobicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeks
Arrowhead PharmaceuticalsARO-APOC3
NewAmsterdam PharmaObicetrapib
NewAmsterdam PharmaObicetrapib 5mg
NewAmsterdam PharmaObicetrapib
Jazz PharmaceuticalsGWP42003
Eli Lilly and CompanyLY3885125
Arrowhead PharmaceuticalsARO-ANG3
Eli Lilly and CompanyLY3202328
NovartisLipid panel
SanofiGuideline recommended feedback

Clinical Trials (14)

Total enrollment: 1,536 patients across 14 trials

NCT01462877Abbottfenofibrate

A Study to Evaluate Fenofibrate Combination With Statin in Chinese Patients With Dyslipidemic

Start: Oct 2011Est. completion: Mar 2014506 patients
Phase 4Completed
NCT06005597NewAmsterdam PharmaCombination Therapy

Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies

Start: Mar 2024Est. completion: Oct 2024
Phase 3Completed
NCT05425745NewAmsterdam PharmaObicetrapib

Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies.

Start: Jul 2022Est. completion: May 2024
Phase 3Completed
NCT06496243NewAmsterdam Pharmaobicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeks

Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels

Start: Dec 2024Est. completion: Feb 2026
Phase 2Recruiting
NCT05413135Arrowhead PharmaceuticalsARO-APOC3

Study of ARO-APOC3 in Adults With Dyslipidemia

Start: Jul 2022Est. completion: Sep 2025418 patients
Phase 2Completed
NCT05266586NewAmsterdam PharmaObicetrapib

Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy

Start: Mar 2022Est. completion: Sep 2022
Phase 2Completed
NCT04770389NewAmsterdam PharmaObicetrapib 5mg

Randomized Study of Obicetrapib in Combination With Ezetimibe

Start: Feb 2021Est. completion: Jun 2021
Phase 2Completed
NCT04753606NewAmsterdam PharmaObicetrapib

Randomized Study of Obicetrapib as an Adjunct to Statin Therapy

Start: Feb 2021Est. completion: Aug 2021
Phase 2Completed
NCT01217112Jazz PharmaceuticalsGWP42003

GWMD1092 - GWP42003 : GWP42004 Together Plus Alone in Type II Diabetes

Start: Oct 2010Est. completion: Sep 201262 patients
Phase 2Completed
NCT06007651Eli Lilly and CompanyLY3885125

A Study of LY3885125 in Participants With Dyslipidemia or Non-Alcoholic Fatty Liver Disease (NAFLD)

Start: Aug 2023Est. completion: Feb 202549 patients
Phase 1Terminated
NCT03747224Arrowhead PharmaceuticalsARO-ANG3

Study of ARO-ANG3 in Healthy Volunteers and in Dyslipidemic Patients

Start: Jan 2019Est. completion: May 202193 patients
Phase 1Completed
NCT02714569Eli Lilly and CompanyLY3202328

A Study to Evaluate LY3202328 in Overweight Healthy Participants and Dyslipidemia

Start: Mar 2016Est. completion: Feb 201760 patients
Phase 1Completed
NCT06388668NovartisLipid panel

Lipid Testing After Myocardial Infarction at the Montreal Heart Institute

Start: Jun 2024Est. completion: May 2026100 patients
N/ARecruiting
NCT03994575SanofiGuideline recommended feedback

North American Acute Coronary Syndrome (ACS) Reflective III Pilot

Start: Mar 2019Est. completion: May 2021248 patients
N/ACompleted

Related Jobs in Metabolic Diseases

Senior Medical Science Liaison - Obesity - Northern CA, Central CA, NV

Amgen
California - San Francisco, US
20h ago

(Sr) Scientist Analytical Chemistry – Mass Spectrometry (Temporary role 3 years)

Johnson & Johnson
Beerse, Antwerp, Belgium
Yesterday

Computational Chemist

Topos Bio
San Francisco Office
2d ago

Associate Director, Legal Operations & Contracts Management

Kailera Therapeutics
Massachusetts
4d ago
From $155K/yr

Senior Specialist, Quality Management Systems

Crinetics Pharmaceuticals
San Diego, CA
4d ago
$91K - $114K/yr

Director, Quality Systems, Project Management, QRM, RS

Crinetics Pharmaceuticals
US California
4d ago
$178K - $223K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
2 actively recruiting trials targeting 1,536 patients
9 companies competing in this space

Related Indications

Diabetes(737)Diabetes Mellitus, Type 2(485)Obesity(246)Type 2 Diabetes(207)Type 2 Diabetes Mellitus(190)Diabetes Mellitus(127)Diabetes Mellitus, Type 1(95)Type 1 Diabetes Mellitus(51)Type 1 Diabetes(50)Dyslipidemia(45)